Precision BioSciences Inc (DTIL)vsMerck & Company Inc (MRK)
DTIL
Precision BioSciences Inc
$7.28
-3.77%
HEALTHCARE · Cap: $288.76M
MRK
Merck & Company Inc
$144.52
-2.23%
HEALTHCARE · Cap: $362.27B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 149489% more annual revenue ($67.38B vs $45.04M). MRK leads profitability with a 3.6% profit margin vs -85.6%. DTIL trades at a lower P/E of 30.3x. MRK earns a higher WallStSmart Score of 42/100 (D).
DTIL
Avoid26
out of 100
Grade: F
MRK
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+56.6%
Fair Value
$9.38
Current Price
$7.28
$2.10 discount
Margin of Safety
-74.0%
Fair Value
$84.93
Current Price
$144.52
$59.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37272.0% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 35.2%
Generating 5.5B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : DTIL
The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : DTIL
The primary concerns for DTIL are P/E Ratio, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
DTIL profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
DTIL carries more volatility with a beta of 1.35 — expect wider price swings.
DTIL is growing revenue faster at 37272.0% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (42/100 vs 26/100). DTIL offers better value entry with a 56.6% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Precision BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?